Navigation Links
2 Years of Hormone Use May Be 'Safe'
Date:2/3/2009

Cancer risk doesn't rise until third year, study finds

TUESDAY, Feb. 3 (HealthDay News) -- A potential two-year "safe period" for hormone replacement therapy has been identified by American Cancer Society epidemiologists, who also confirmed that using estrogen-plus-progesterone therapy increases the risk for both ductal and lobular breast cancer far more than taking estrogen alone.

The finding follows a report last month from the Society of Obstetricians and Gynaecologists of Canada that women have been needlessly scared away from using hormone therapy during menopause.

Researchers for the U.S. study followed 68,369 postmenopausal women who were cancer-free when the study began in 1992. They were followed through mid-2005.

Along with confirming previous findings of increased breast cancer risk from combination therapy, the research team also found that the cancer risk increases substantially within three years of starting estrogen-plus-progesterone therapy.

The risk for lobular cancer doubled after three years of estrogen-plus-progesterone use, and ductal cancer doubled in risk after 10 years of use, the study found.

With estrogen-only therapy, the likelihood of developing lobular cancer increased 50 percent after 10 years of use, but there was no increase in the risk for ductal cancer, even after 20 years.

However, the study found that women who used an estrogen-progesterone combination for less than two years had no increased risk, possibly representing a safe period for combination therapy, the researchers said.

Nor was added risk found for women who had used the hormone combination but had been off the therapy for two or more years.

The researchers said that this suggests a window of two to three years for the risks associated with the estrogen-plus-progesterone combination to become apparent after initial use and to diminish after the therapy is halted.

The study was expected to appear in the March issue of the journal Cancer and has been published online.

In the Canadian report, the doctors' group said that it was revising its guidelines for use of hormone replacement therapy, because evidence has shown that the drugs offer a safe and viable option for women experiencing troublesome menopause symptoms.

However, it was recommending that hormone therapy should start early in menopause and be used only short-term, according to an account in the Canadian Press.

In 2002, a large U.S. study found that menopausal hormone therapy increased the risk of heart attack and stroke. But, the Canadian experts said, that study incorrectly concluded that the increased risk seen in older women applied to all women who use the drugs.

More information

The U.S. National Cancer Institute has more about hormone therapy and cancer.



-- Robert Preidt



SOURCES: American Cancer Society, news release, Feb. 2, 2009; Jan. 22, 2009, Canadian Press


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Divorce, antidepressants, or weight gain/loss can add years to your face
2. Divorce, Antidepressants, or Weight Gain/Loss Can Add Years to Your Face
3. Cementless cup device developed for hip replacements shows durability after more than 20 years
4. DNA Solves Switched at Birth Mystery ... After 57 Years
5. After Eight Years of Injustice, International Family Planning Funding is Restored
6. Looking Years Younger, Raising a Few Brows
7. As New Administration Takes Office, Deloitte Report Identifies $530 Billion Savings Opportunity for Health Care Reform Over Next 10 Years
8. New drug development still takes 8 years despite faster FDA review, according to Tufts CSDD
9. Taking 20 Years Off Her Health and Looks, RealAge Member Flaunts It on Oprah Show
10. Max Muscle Sports Nutrition Offers $25,000 Reward For Your New Years Resolution
11. Miami Physician Sentenced to 30 Years in Prison for $11 Million Medicare Fraud Scheme
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
2  Years of Hormone Use May Be 'Safe'
(Date:5/24/2017)... , ... May 24, 2017 , ... ... background. Understanind and choosing the most appropriate instruments for research and understanding the ... research finding. This webinar will focus on innovations in stereo microscopy for brightfield ...
(Date:5/24/2017)... ... , ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming ... referral. Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on ... no longer need to feel the esthetic effects of wires and brackets when they ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... reproductive tract in which the endometrial lining of the uterus spreads into ... pain. Patients experiencing painful intercourse, painful periods, pelvic pain, or irregular bleeding ...
(Date:5/24/2017)... ... May 24, 2017 , ... Rob Lowe is a ... developed for Public Television. “Informed” brings the public important topics from all aspects of ... of the feet and issues surrounding feet and ankles. , Podiatry is essential to ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a ... today that its iClinic V12.2 solution has achieved approval from National Center for ... PCMH 2017 standards which emphasize team-based care with a significant focus on the ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, Inc. ... technology solutions to improve the clinical effectiveness and ... for the first quarter ended March 31, 2017. ... enable our customers to identify when preventive care ... before events like heart attacks or strokes occur," ...
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
(Date:5/4/2017)... MONTREAL , May 4, 2017  Fortuna Fix Inc. (" ... aiming to be the first to eliminate the need for ... autologous cells to treat neurodegenerative diseases. Fortuna ... ("SAB") with Professor Michael Fehlings , MD, PhD; Father ... Hack , MD, MPH; and Professor James Giordano , ...
Breaking Medicine Technology: